Iterative approach to computational enzyme design by Privett, Heidi K. et al.
Supporting	  Information	  	  	  
SI	  Materials	  and	  Methods	  	  	  
TS	  Structure.	  	  The	  TS	  structure	  was	  taken	  from	  a	  previously	  published	  ab	  initio	  calculation	  (1).	  	  To	  assist	  with	  defining	  geometric	  constraints	  in	  the	  calculations,	  a	  pseudoatom	  (PSA)	  with	  no	  charge	  and	  a	  negligible	  radius	  was	  added	  0.01	  Å	  from	  the	  acidic	  proton	  in	  the	  plane	  of	  the	  TS.	  	  	  
Scaffold	   Selection.	   	   For	   the	   initial	   design,	   the	   xylanase	   from	   the	   thermophilic	   fungus	  T.	  
aurantiacus	  (TAX)	  was	  selected	  as	  the	  scaffold.	  	  The	  crystal	  structure	  (PDB	  code:	  1GOR)	  is	  1.7	  Å	  resolution	  with	  xylobiose	  bound	  in	  the	  active	  site	  (2).	   	  The	  PDB	  structure	  was	  used	  without	  minimization,	  and	  hydrogens	  were	  added	  with	  Molprobity	  (3).	  	  Later	  designs	  used	  the	  native	  binding	  pockets	  of	  T.	  maritima	  imidazoleglycerolphosphate	  synthase	  (PDB	  code:	  1THF)	  (4)	  and	  S.	  solfataricus	  indole-­‐3-­‐glycerolphosphate	  synthase	  (PDB	  code:	  1A53)	  (5)	  as	  scaffolds.	  
Gene	   Synthesis	   and	   Cloning.	   	   The	   gene	   for	   the	   wild-­‐type	   scaffold	   was	   back-­‐translated	  from	   the	  protein	   sequence	  using	   the	   codon	  usage	  bias	  of	  Escherichia	   coli	   in	  DNA	  2.0	   (6).	  	  The	   DNA	   sequence	   for	   a	   Factor	   Xa	   cleavage	   site	   and	   six-­‐histidine	   purification	   tag	   were	  added	  to	  the	  3ʹ′	  end	  of	  the	  gene.	  	  Overlapping	  oligonucleotides	  spanning	  the	  gene	  sequence	  and	  flanking	  primers	  were	  designed	  using	  the	  Assembly	  PCR	  Oligo	  Maker	  web	  server	  (7).	  	  The	   full-­‐length	  gene	  was	  constructed	  by	  recursive	  PCR	  using	  a	  method	  based	  on	   the	  one	  described	   by	   Stemmer	   and	   coworkers	   (8).	   	   After	   amplification,	   the	   full-­‐length	   gene	  was	  inserted	  into	  a	  pET11a	  vector	  (Novagen)	  using	  BamHI	  and	  NdeI.	  
Multiple	  Protein	  Expression	  and	  Purification	  Protocols.	  	  To	  confirm	  the	  activity	  of	  HG-­‐3	  (HG-­‐2/S265T),	   independent	  expression	  and	  purification	  schemes	  were	  carried	  out	  at	  two	  different	  laboratories.	  	  (i)	  All	  the	  designed	  enzymes	  and	  their	  variants	  were	  expressed	  and	  purified	   in	   the	   Division	   of	   Chemistry	   and	   Chemical	   Engineering,	   California	   Institute	   of	  Technology,	  Pasadena,	  CA	  using	  protocol	  1.	   	   (ii)	  HG-­‐3	  and	  point	  mutants	  were	  expressed	  and	   purified	   using	   independent	   protocols	   in	   the	   Laboratory	   of	   Organic	   Chemistry,	   ETH	  Zurich,	  Zurich,	  Switzerland	  using	  protocol	  2.	  	  Comparable	  catalytic	  activity	  was	  observed	  in	  both	  labs.	  
	  
Protein	  Expression	  and	  Purification:	  	  Protocol	  1.	  	  HG-­‐2,	  HG-­‐3,	  1A53-­‐1,	  1A53-­‐2,	  1A53-­‐3,	  1THF-­‐1,	  1THF-­‐2	  and	  all	  variants	  were	  expressed	  in	  BL-­‐21	  (DE3)	  Escherichia	  coli	  cells	  in	  LB-­‐Amp.	  	  A	  single	  colony	  was	  used	  to	  inoculate	  overnight	  cultures	  of	  LB-­‐Amp,	  grown	  at	  37	  °C.	  	  One	   liter	   of	   LB	   medium	   supplemented	   with	   100	   mg/L	   of	   ampicillin	   (LB-­‐Amp)	   was	  inoculated	  with	  30	  mL	  of	  the	  overnight	  culture.	  	  The	  cells	  were	  grown	  with	  shaking	  at	  37	  °C	  until	  OD600	  ~	  0.3;	   the	   temperature	  was	   then	  reduced	   to	  18	   °C	  until	  OD600	  ~	  0.6.	   	  Protein	  expression	   was	   induced	   with	   1	   mM	   isopropyl	   β-­‐D-­‐1-­‐thiogalactopyranoside	   (IPTG)	   and	  carried	  out	  at	  18	  °C	  for	  12-­‐18	  h.	  	  Cells	  were	  harvested	  by	  centrifugation	  and	  resuspended	  in	  30	  mL	  lysis	  buffer	  (20	  mM	  Tris	  pH	  7.4,	  300	  mM	  NaCl)	  containing	  10	  mM	  imidazole;	  10	  mM	  MgCl2,	   ribonuclease	   A,	   and	   deoxyribonuclease	   I	   were	   added	   and	   the	   cells	   were	   lysed	  mechanically	  with	  an	  Emulsiflex-­‐C5	  (Avestin).	  	  The	  soluble	  fraction	  was	  incubated	  for	  ~1	  h	  with	   1	   mL	   Ni-­‐NTA	   resin	   (Qiagen)	   pre-­‐equilibrated	   with	   10	   bed	   volumes	   of	   lysis	   buffer	  containing	   10	   mM	   imidazole.	   	   The	   resin	   was	   washed	   in	   a	   gravity	   column	   with	   10	   bed	  
volumes	  of	  buffer	  2	   (lysis	  buffer	  with	  20	  mM	   imidazole)	  and	  purified	  protein	  was	  eluted	  with	   3	   bed	   volumes	   of	   buffer	   3	   (lysis	   buffer	   with	   250	   mM	   imidazole).	   	   The	   eluate	   was	  concentrated	   using	   Amicon	   centrifugal	   concentrators	   (Millipore)	   and	   the	   buffer	   was	  exchanged	  to	  50	  mM	  sodium	  citrate,	  150	  mM	  NaCl	  pH	  5.5	  (for	  1GOR-­‐based	  designs)	  or	  25	  mM	   HEPES,	   100	   mM	   NaCl	   pH	   7.25	   (for	   1THF-­‐	   and	   1A53-­‐based	   designs)	   using	   PD-­‐10	  desalting	   columns	   (GE).	   	   Protein	   purity	   was	   confirmed	   by	   SDS-­‐PAGE.	   	   The	   molecular	  weights	   of	   all	   proteins	   were	   confirmed	   by	   electrospray	   ionization	   mass	   spectrometry.	  Protein	  concentrations	  were	  determined	  by	  measuring	  the	  absorbance	  at	  280	  nm	  using	  the	  calculated	  extinction	  coefficient	  (ε	  =	  57,410	  M-­‐1	  cm-­‐1).	  	  	  	  
Protein	  Expression	  and	  Purification:	  Protocol	  2.	   	  Here,	  protein	  expression	  was	  carried	  out	  as	  above	  except	  that	  cultures	  contained	  150	  mg/L	  ampicillin,	  expression	  cultures	  were	  inoculated	  with	  the	  overnight	  culture	  at	  a	  ratio	  of	  1:100,	  and	  induction	  was	  carried	  out	  for	  24	  h.	   	  After	  24	  h,	   the	  cells	  were	  harvested	  and	  resuspended	   in	  sonication	  buffer	   (20	  mM	  Tris	   pH	  7.4,	   300	  mM	  NaCl)	   containing	   10	  mM	   imidazole.	   	   Cell	   lysis	  was	   achieved	   by	   the	  addition	  of	  1	  mg/mL	  lysozyme	  and	  subsequent	  sonication.	  The	  soluble	  fraction	  was	  applied	  to	  Ni-­‐NTA	  slurry	  (Qiagen),	  washed	  with	  20	  mM	  imidazole	  and	  then	  with	  32.5	  mM	  imidazole	  before	  elution	  with	  250	  mM	  imidazole	  in	  sonication	  buffer.	  	  The	  protein	  was	  dialyzed	  into	  20	   mM	   Tris,	   20	   mM	   NaCl	   (pH	   8.0)	   for	   16	   h	   and	   then	   purified	   by	   anion	   exchange	  chromatography	   (MonoQ	   column,	   GE	   Healthcare)	   in	   the	   same	   buffer,	   eluting	  with	   a	   salt	  gradient	  (20	  mM	  to	  1,000	  mM	  NaCl).	  	  The	  protein	  was	  concentrated	  using	  an	  Amicon	  Ultra-­‐15	  unit	  (Millipore).	  	  	  	  
5-­Nitrobenzisoxazole	   (5-­NBZ).	   This	   compound	   was	   prepared	   according	   to	   literature	  procedures	  (9,	  10).	  	  
CD	   Spectroscopy.	   	   Far-­‐UV	   spectra	   were	   measured	   at	   25	   °C	   using	   an	   Aviv	   62DS	  spectropolarimeter	   equipped	   with	   a	   thermoelectric	   temperature	   controller	   (Aviv	  Associates,	   Lakewood,	   NJ).	   	   Thermal	   denaturations	   were	   monitored	   at	   222	   nm.	   	   All	  experiments	  were	  carried	  out	  in	  a	  1	  mM	  cuvette	  containing	  10	  µM	  protein	  in	  25	  mM	  HEPES	  pH	  7.25,	  100	  nM	  NaCl.	   	  Apparent	  midpoints	  of	   thermal	  denaturation	   (Tm)	  were	  obtained	  using	   the	  equation	  of	  Minor	  and	  Kim	  (11).	   	  Tm	  values	   should	  be	  considered	  approximate	  and	  not	  actual	  thermodynamic	  parameters,	  as	  the	  denaturation	  was	  not	  reversible	   in	  any	  case	  tested.	  	  
Mass	  Spectrometry.	   	  The	  protein	  sample	  was	  desalted	  using	  a	  C4	  ZipTip	  (Millipore)	  and	  measured	   in	  50%	  acetonitrile/0.2%	  formic	  acid	  (pH	  2.0)	  by	  electrospray	   ionization	  mass	  spectrometry	   (ESI-­‐MS)	   on	   a	   Q-­‐TOF	   Ultima	   mass	   spectrometer	   (Waters).	   	   The	   mass	  spectrum	  of	  each	  protein	  was	  deconvoluted	  using	  MaxEnt1	  software.	  	  
Protein	  Crystallization	  and	  Crystallography.	   	  Crystals	  of	  HG-­‐1	  (expressed	  and	  purified	  using	  protocol	  1)	  were	  obtained	  at	  room	  temperature	  from	  a	  4	  mL	  hanging	  drop	  containing	  5	  mg/mL	  HG-­‐1	   in	   buffer	   containing	  0.8	  M	  potassium-­‐sodium	   tartrate,	   0.1	  M	  Tris	   pH	  8.5,	  0.5%	  PEG-­‐MME	  5000.	   	  The	  crystal	  was	  cryo-­‐protected	  in	  the	  reservoir	  solution	  with	  15%	  ethylene	   glycol.	   	   Data	   were	   collected	   using	   a	   MicroMax-­‐007HF	   X-­‐ray	   generator	   with	   a	  RAXIS	   IV++	   detector	   (Rigaku	   Corp.)	   	   All	   data	  were	   processed	   using	   CrystalClear	   (Rigaku	  Corp.)	  and	  MOSFLM	  (12).	  
Crystals	   of	   HG-­‐2/NBT,	   1A53-­‐2/NBT,	   and	   apo	   1A53-­‐2	   were	   obtained	   through	   sitting-­‐drop	  vapor	  diffusion	  carried	  out	  at	  room	  temperature	  with	  a	  protein	  concentration	  of	  9.5	  mg/mL.	   	   Co-­‐crystallization	   for	   HG-­‐2/NBT	   and	   1A53-­‐2/NBT	   was	   achieved	   through	   pre-­‐incubation	  of	  the	  protein	  with	  5	  mM	  5-­‐nitrobenzotriazole	  (5-­‐NBT,	  Ryan	  Scientific)	  prior	  to	  crystallization	   trials.	   	   A	   100	  mM	   stock	   solution	   of	   5-­‐NBT	  was	   prepared	   in	   DMSO	   before	  combining	  with	  the	  protein.	   	  Reservoir	  solutions	  for	  HG-­‐2/NBT	  (0.1	  M	  sodium	  acetate	  pH	  4.6,	  2	  M	  ammonium	  sulfate),	  1A53-­‐2/NBT	  (0.1	  M	  sodium	  citrate/citric	  acid	  pH	  5.6,	  0.2	  M	  potassium	  sodium	  tartrate,	  2	  M	  ammonium	  sulfate),	  and	  apo	  1A53-­‐2	  (0.1	  M	  Bis-­‐Tris	  pH	  5.5,	  0.2	  M	  ammonium	  acetate,	  and	  25%	  PEG	  3350)	  were	  combined	  with	  protein	  in	  a	  1:1	  ratio.	  	  A	   single	   HG-­‐2/NBT,	   multiple	   cube-­‐like	   1A53-­‐2/NBT,	   and	   several	   plate-­‐like	   apo	   1A53-­‐2	  crystals	  developed	  with	   a	  minimum	  growth	   time	  of	   one	  month.	   	   The	   crystals	  were	   cryo-­‐protected	  with	  paraffin	  oil	  and	  shipped	  to	  the	  Stanford	  Synchrotron	  Radiation	  Lightsource,	  beamline	   12-­‐2	   for	   remote	   data	   collection.	   	   Diffraction	   data	   were	   processed	   with	   the	  program	  MOSFLM	  using	  the	  interface	  iMOSFLM	  (12).	  Data	  were	  scaled	  using	   the	  program	  SCALA	  (13).	   	  Molecular	  replacement	  was	  carried	  out	  with	  PHASER	  (13,	  14).	   	  The	  coordinates	  for	  Thermoascus	  aurantiacus	  xylanase	  I	  (PDB	  code:	  1GOR)	  (2)	  and	  Sulfolobus	  solfataricus	  (PDB	  code:	  1A53)	  (5)	  were	  modified	  to	  contain	  alanine	  at	  all	  point	  mutations	  in	  the	  designs	  and	  were	  subsequently	  used	  as	  the	  molecular	  replacement	   starting	   models	   for	   HG-­‐2	   and	   1A53-­‐2,	   respectively.	   	   Model	   building	   was	  carried	  out	  using	  COOT	  (15).	   	  The	  structure	  was	  refined	  using	  REFMAC	  (16)	  and	  PHENIX	  (17).	   Backbone	   density	   for	   the	   HG-­‐2	   structure	   appeared	   in	   two	   distinct	   backbone	  conformations	  in	  chain	  B,	  similar	  to	  the	  dual	  backbone	  conformation	  found	  in	  the	  structure	  of	   red	   fluorescent	   protein	   variant	   FP611	   (PDB	   code:	   3E5T)	   (18).	   	   The	   apo	   structure	   of	  1A53-­‐2	   was	   processed	   with	   a	   twinning	   fraction	   of	   0.13	   towards	   the	   end	   of	   refinement.	  	  Crystallographic	  data	  statistics	  are	  summarized	  in	  Table	  S2.	  
	  
Kinetic	  Measurements.	  	  Assays	  were	  carried	  out	  with	  5	  µM	  protein	  (purified	  via	  protocol	  1)	  in	  25	  mM	  HEPES,	  pH	  7.25,	  100	  mM	  NaCl	  at	  27	  °C.	  	  Substrate	  concentrations	  between	  16	  







Km + [S]0 	  	  where	  v0	   is	  the	  initial	  reaction	  rate,	  [E]T	   is	  the	  total	  enzyme	  concentration,	  and	  [S]0	   is	  the	  initial	  substrate	  concentration.	  	  In	  the	  cases	  where	  the	  enzyme	  was	  not	  saturated	  because	  of	  limited	  substrate	  solubility,	  the	  data	  were	  fit	  to	  a	  line	  to	  determine	  kcat/Km.	  Where	  indicated	  in	  Table	  1,	  assays	  were	  carried	  out	  using	  1	  µM	  of	  protein	  purified	  via	  expression	  protocol	  2	   in	  50	  mM	  phosphate	  buffer	  (pH	  7.0),	  containing	  100	  mM	  NaCl	  and	  2%	   acetonitrile.	   	   Reactions	   were	   initiated	   by	   adding	   different	   amounts	   of	   5-­‐NBZ	   in	  acetonitrile	  (25	  μM	  to	  1.25	  mM	  final	  concentration).	  	  Product	  formation	  was	  monitored	  at	  380	  nm	  in	  a	  Lambda	  35	  UV/Vis	  spectrometer	  (PerkinElmer)	  at	  27	  °C.	  	  




1+10pka1− pH +10pH− pKa2 	  	  
Ki	   Determination.	   	   After	   preincubation	   of	   1	   μM	   HG-­‐3	   with	   varying	   concentrations	   of	  5-­‐nitrobenzotriazole	  (0.001–1000	  μM	  final	  concentrations)	  in	  50	  mM	  acetate	  buffer	  (pH	  5)	  containing	  100	  mM	  NaCl,	  2%	  acetonitrile,	   and	  1%	  DMSO,	   the	   reactions	  were	   initiated	  by	  addition	   of	   5-­‐NBZ	   (250	   μM	   final	   concentration).	   	   Product	   formation	   was	   monitored	   as	  described	   above.	   	   The	   IC50	   value	  was	   determined	  by	   curve	   fitting	   (Hill-­‐Slope	  model,	  vi	   at	  infinite	   inhibitor	   concentration	   was	   set	   to	   zero)	   and	   subsequently	   converted	   into	   the	  corresponding	  Ki	   value	  using	   the	  Cheng-­‐Prusoff	  equation	  Ki	   =	   [IC50]/(1+[S]/Km)	   (19).	  The	  
Km	   value	  was	  determined	   independently	   in	   the	   same	  buffer	   and	  under	   identical	   reaction	  conditions	  using	  the	  protocol	  described	  above.	  	  
MD	  Simulations.	   	  MD	  simulations	  were	  carried	  out	   for	  20	  ns	   for	  each	  enzyme-­‐substrate	  complex	  at	  NPT	  conditions	  (constant	  number	  of	  particles,	  pressure,	  and	  temperature)	  with	  a	  pressure	  of	  1	  bar	  and	  temperature	  of	  300	  K.	  	  The	  TIP3P	  explicit	  solvent	  model	  (20)	  was	  used	  to	  solvate	  the	  protein	  in	  an	  octahedral-­‐shaped	  volume,	  ensuring	  a	  solvent	  layer	  of	  at	  least	   10	   Å	   from	   any	   point	   on	   the	   protein	   surface.	   	   Each	   face	   of	   the	   octahedral	   box	   is	  connected	  to	  a	  mirror	  image	  of	  itself,	  which	  allows	  the	  system	  to	  be	  treated	  with	  periodic	  boundary	   conditions.	   	   This	   ensures	   equilibration	   through	   diffusion	  while	   the	   number	   of	  particles	  is	  kept	  constant.	   	  The	  temperature	  is	  regulated	  and	  evenly	  distributed	  through	  a	  Langevin	   equilibration	   scheme.	   	   The	   5-­‐NBZ	   substrate	  was	   parameterized	   from	   quantum	  mechanical	   calculations	   in	   order	   to	   be	   treated	   correctly	   by	   the	   AMBER	   force	   field	   (21).	  	  Prior	  to	  production	  MD,	  the	  substrate	  was	  superimposed	  onto	  the	  ab	  initio	  transition	  state	  in	   the	   active	   site	   of	   the	   computationally	   designed	   protein	   model.	   The	   structure	   of	   the	  resulting	  protein-­‐substrate	  complex	  was	  optimized	  and	  heated	  to	  300	  K	  in	  six	  50	  ps	  steps	  for	  a	  total	  of	  300	  ps	  at	  NVT	  conditions,	  and	  then	  equilibrated	  at	  NPT	  conditions	  for	  2	  ns.	  The	  structural	  models	  predicted	  by	   the	  computational	  design	  algorithm	  were	  used	  as	  starting	  structures.	  	  Substrate	  parameters	  were	  generated	  within	  the	  Antechamber	  module	  of	  AMBER	  10	  (22)	  using	  the	  general	  AMBER	  force	   field,	  with	  partial	  charges	  set	   to	   fit	   the	  electrostatic	  potential	  generated	  at	  HF/6-­‐31G*	  by	  RESP	  (23).	  	  The	  charges	  were	  calculated	  according	  to	  the	  Merz-­‐Singh-­‐Kollman	  scheme	  (24,	  25)	  using	  Gaussian	  03	  (26).	  	  The	   structures	   were	   immersed	   in	   a	   truncated	   octahedral	   box	   with	   a	   10	   Å	   buffer	   of	  TIP3P	   (20)	  water	  molecules,	   resulting	   in	   the	  addition	  of	  up	   to	  16,000	   solvent	  molecules,	  depending	  on	   the	   scaffold.	   	  The	   systems	  were	  neutralized	  by	  addition	  of	   explicit	   counter	  ions.	   	   All	   subsequent	   calculations	   were	   done	   using	   the	   widely	   tested	   Stony	   Brook	  modification	   of	   the	   AMBER	   99	   force	   field	   (27).	   A	   two-­‐stage	   geometry	   optimization	  approach	   was	   utilized,	   initially	   minimizing	   the	   positions	   of	   water	   molecules	   and	   ions,	  followed	  by	  an	  unrestrained	  minimization	  of	  all	  atoms.	  	  The	  systems	  were	  heated	  gently	  in	  six	  steps	  of	  50	  ps	  from	  0	  to	  300	  K	  at	  constant	  volume	  periodic	  boundary	  conditions.	  	  Weak	  
harmonic	   restraints	   of	   30	   kcal/mol	   were	   applied	   to	   the	   solute,	   and	   the	   Langevin	  equilibration	  scheme	  was	  used	  to	  control	  and	  equalize	  the	  temperature.	  	  The	  time	  step	  was	  kept	   at	   1	   fs	   during	   the	   heating	   stages,	   allowing	   potential	   inhomogeneities	   to	   self-­‐adjust.	  	  Each	  system	  was	  then	  equilibrated	  for	  2	  ns	  with	  a	  2	  fs	  time	  step	  at	  a	  constant	  pressure	  of	  1	  atm.	   	  Water	  molecules	  were	   triangulated	  with	   the	   SHAKE	   algorithm	   such	   that	   the	   angle	  between	   the	   hydrogen	   atoms	   is	   kept	   fixed.	   	   A	   20	   ns	   production	   MD	   simulation	   was	  performed	  for	  each	  of	  the	  systems	  (with	  and	  without	  the	  substrate	  bound	  to	  the	  active	  site)	  using	  PMEMD	  (28).	  	  Geometries	  and	  velocities	  were	  saved	  every	  100	  steps	  (0.2	  ps),	  which	  resulted	   in	   a	   total	   of	   10,000	  and	  100,000	   frames	   from	  each	  production	   run.	   	   Long-­‐range	  electrostatic	   effects	  were	  modeled	  using	   the	  particle-­‐mesh-­‐Ewald	  method	   (29).	   	  Post-­‐MD	  data	  extraction	  and	  analysis	  were	  performed	  using	  the	  ptraj	  module	  of	  AMBER	  10	  (22)	  and	  the	  statistical	  analysis	  software	  OriginPro8	  (Origin	  Lab).	  	  
QM	  Calculations.	  	  Theozyme	  DFT	  B3LYP/6-­‐31G(d)	  transition	  state	  (TS)	  calculations	  were	  performed	  on	  a	  model	   system	   that	   consists	  of	   the	   substrate,	   acetate	   as	   the	  general	  base,	  and	  methanol	  as	  the	  hydrogen-­‐bond	  donor.	  The	  distance	  versus	  angle	  scatter-­‐point	  of	  the	  deprotonation	  is	  plotted	  in	  Figure	  3C	  and	  3D.	  
Table S1.  Geometric constraints for the contact between the TS and the catalytic 
residues 
 
Contact: Asp/Glu to H3* 
Residue Type Atom1 Atom2 Atom3 Atom4 Min†,‡ Max†,‡ 
Asp Distance OD1 H3   1.0 1.6 
 Angle OD2 OD1 H3  59.0 121.0 
 Torsion CG OD2 OD1 H3 159.0 201.0 
 Angle OD1 H3 PSA  59.0 121.0 
 Torsion OD2 OD1 H3 PSA 0.0 360.0 
 Torsion OD1 H3 PSA C3 159.0 201.0 
        
Asp Distance OD2 H3   1.0 1.6 
 Angle OD1 OD2 H3  59.0 121.0 
 Torsion CG OD1 OD2 H3 159.0 201.0 
 Angle OD2 H3 PSA  59.0 121.0 
 Torsion OD1 OD2 H3 PSA 0.0 360.0 
 Torsion OD2 H3 PSA C3 159.0 201.0 
        
Glu Distance OE1 H3   1.0 1.6 
 Angle OE2 OE1 H3  59.0 121.0 
 Torsion CD OE2 OE1 H3 159.0 201.0 
 Angle OE1 H3 PSA  59.0 121.0 
 Torsion OE2 OE1 H3 PSA 0.0 360.0 
 Torsion OE1 H3 PSA C3 159.0 201.0 
        
Glu Distance OE2 H3   1.0 1.6 
 Angle OE1 OE2 H3  59.0 121.0 
 Torsion CD OE1 OE2 H3 159.0 201.0 
 Angle OE2 H3 PSA  59.0 121.0 
 Torsion OE1 OE2 H3 PSA 0.0 360.0 
 Torsion OE2 H3 PSA C3 159.0 201.0 
 
	  
Contact: Ser/Thr/Tyr to O1* 
Residue Type Atom1 Atom2 Atom3 Atom4 Min†,‡ Max†,‡ 
Ser Distance OG O1   2.6 4.0 
 Angle OG HG O1  150.0 180.0 
 Angle HG O1 N2  100.0 160.0 
 Torsion HG O2 N2 C3 120.0 240.0 
        
Thr Distance OG1 O1   2.6 4.0 
 Angle OG1 HG1 O1  150.0 180.0 
 Angle HG1 O1 N2  100.0 160.0 
 Torsion HG1 O2 N2 C3 120.0 240.0 
        
Tyr Distance OH O1   2.6 4.0 
 Angle OH HH O1  150.0 180.0 
 Angle HH O1 N2  100.0 160.0 
 Torsion HH O2 N2 C3 120.0 240.0 
*Three contacts were required:  Asp/Glu, Phe/Trp, and Ser/Thr/Tyr. 
†Distance measurements are given in Å. 
‡Angle, torsion, and plane measurements are given in degrees. 
	  
Contact: Phe/Trp to PS2* 
Residue Type Atom1 Atom2 Atom3 Atom4 Atom5 Atom6 Min†,‡ Max†,‡ 
Phe Pseudo-atom PS1, equidistant between CE1 and CD2    
 Pseudo-atom PS2, equidistant between C4 and C9     
 Distance PS1 PS2     3.0 4.0 
 Plane CG CE1 CE2 C5 C8 N2 0.0 40.0 
      
Trp Pseudo-atom PS1, equidistant between CE2 and CD2    
 Pseudo-atom PS2, equidistant between C4 and C9     
 Distance PS1 PS2     3.0 4.0 
 Plane CD1 CE3 CH2 C5 C8 N2 0.0 40.0 	  	  	  	  	  	  	  	  	  	  	  
*Three contacts were required:  Asp/Glu, Phe/Trp, and Ser/Thr/Tyr. 
†Distance measurements are given in Å. 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































   
Table S3.  Data collection and refinement statistics for HG-1, HG-2, and 1A53-2 crystal 
structures 









Data Collection     
Space group P212121 P212121 P3121 P21 
Cell dimensions     
a, b, c, Å 48.3, 72.5, 74.6 75.8, 78.1, 98.2 60.7, 60.7, 120.2 38.0, 46.3, 127.0 
α, β, γ, ° 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 120.0 90.0, 92.0, 90.0 
Resolution, Å 2.0 1.2 1.6 1.5 
Rsym , %* 2.5 (4.4) 4.6 (33.8) 6.6 (50.4) 11.6 (45.6) 
I/σI* 30.7 (21.1) 10.3 (1.9) 8.8 (17.6) 4.8 (2.0) 
Completeness, %* 99.2 (98.2) 98.8 (96.4) 99.8 (95.8) 99.4 (99.9) 
Redundancy* 2.7 (2.6) 3.5 (2.3) 4.0 (3.7) 2.9 (2.9) 
Wavelength, Å 1.54 0.99 1.01 1.01 
     
Refinement     








Number of reflections    
Working set 17130 158059 37189 67105 
Test set 874 8337 1856 2041 
Rwork/Rfree ,% 16.7/22.9 15.7/19.6 17.2/21.0 20.2/25.1 
Number of atoms     
Protein 2326 4591 2007 4089 
Ligand/Ion 0 50 72 5 
Water 218 670 181 237 
RMS deviations     
Bond lengths, Å 0.024 0.028 0.027 0.010 
Bond angles, ° 1.80 2.35 2.40 1.24 
Twin fraction  N/A N/A N/A 0.13 
*Parentheses indicate statistics for outer shell of data. 
N/A, not applicable. 
 
Table S4.  Variation of contact geometry for targeted ligand placement 	  
Placement: H3 from Aspartate (OD1)     
Type Atom1 Atom2 Atom3 Atom4 Min*,† Max*, † Step*, † 
Distance OD1 H3   1.1 1.5 0.2 
Angle OD2 OD1 H3  70.0 110.0 20.0 
Torsion CG OD2 OD1 H3 160.0 200.0 20.0 
Angle OD1 H3 PSA  70.0 110.0 20.0 
Torsion OD2 OD1 H3 PSA 0.0 360.0 20.0 
Torsion OD1 H3 PSA C3 160.0 200.0 20.0 
        
Placement: H3 from Aspartate (OD2)     
Type Atom1 Atom2 Atom3 Atom4 Min Max Step 
Distance OD2 H3   1.1 1.5 0.2 
Angle OD1 OD2 H3  70.0 110.0 20.0 
Torsion CG OD1 OD2 H3 160.0 200.0 20.0 
Angle OD2 H3 PSA  70.0 110.0 20.0 
Torsion OD1 OD2 H3 PSA 0.0 360.0 20.0 
Torsion OD2 H3 PSA C3 160.0 200.0 20.0 
        
Placement: H3 from Glutamate (OE1)     
Type Atom1 Atom2 Atom3 Atom4 Min Max Step 
Distance OE1 H3   1.1 1.5 0.2 
Angle OE2 OE1 H3  70.0 110.0 20.0 
Torsion CD OE2 OE1 H3 160.0 200.0 20.0 
Angle OE1 H3 PSA  70.0 110.0 20.0 
Torsion OE2 OE1 H3 PSA 0.0 360.0 20.0 
Torsion OE1 H3 PSA C3 160.0 200.0 20.0 
        
Placement: H3 from Glutamate (OE2)     
Type Atom1 Atom2 Atom3 Atom4 Min Max Step 
Distance OE2 H3   1.1 1.5 0.2 
Angle OE1 OE2 H3  70.0 110.0 20.0 
Torsion CD OE1 OE2 H3 160.0 200.0 20.0 
Angle OE2 H3 PSA  70.0 110.0 20.0 
Torsion OE1 OE2 H3 PSA 0.0 360.0 20.0 
Torsion OE2 H3 PSA C3 160.0 200.0 20.0 
The TS was placed at every indicated geometry for every rotamer of Asp or Glu in the active 
site search calculation.  
*Distance measurements are given in Å. 
†Angle and torsion measurements are given in degrees. 
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Fig. S2.  The active site of HG-1 (A) prior to MD, (B) after MD on the 5-NBZ:HG-1 complex, and (C) after 












Fig. S3.  MD of HG-2 with 5-NBZ bound in an alternative orientation (O2). Distance-time plots and 
projected distance distributions for the contacts between (A) the acidic H of 5-NBZ and the Asp127 
carboxylate oxgens, (B) the heterocycle oxygen of 5-NBZ and the Hs of Lys50, and (C) the nitro group 
oxygens of 5-NBZ and the OH of Ser265. (D) A representative MD snapshot of the HG-2 active site with 






Fig. S4.  (A) RMSD plot of the active site residues of HG-2.  (B) Histogram of distance distribution 











Fig. S5.  Active site of HG-2.  (A) Computational design model.  (B) MD snapshot of state 1.  (C) MD 






Fig. S6. pH rate profile of HG-2/S265T.  HG-2/S265T exhibits a bell-shaped pH-rate 
profile with inflection points at pH 6.0 and 7.8.  The pH optimum of enzymatic activity is 
at pH 7.0.  Experiments were performed in 50 mM acetate (pH 4.0-5.6), phosphate (pH 




Fig. S7.  IC50 determination for 5-nitrobenzotriazole and HG-3.  The assays were carried 
out with 250 µM 5-NBZ, 50 mM acetate pH 5.0, 100 mM NaCl, 2% acetonitrile, 1% 
DMSO, 1 µM enzyme, at 27 °C.  In the curve-fit legend, m1 is the difference between 
(v0/E)min and (v0/E)max, m2 is the IC50, and m3 is the Hill coefficient. In the absence of 
inhibitor, (HG-3) has an apparent kcat = 0.110 ± 0.006 s-1 and Km = 2.14 ± 0.2 mM under 








Fig. S8.  Overlay of 1THF-based KE design models with KE07 design model (30). (A) 1THF-1 
catalytic residues (purple sticks) are overlaid with KE07 catalytic residues (grey sticks). (B) 
1THF-2 catalytic residues (yellow sticks) are overlaid with KE07 catalytic residues (grey sticks). 







Fig. S9.  Overlay of 1A53-based KE design models with KE59 design model (30). (A) 1A53-2 
catalytic residues (green sticks) are overlaid with KE59 catalytic residues (grey sticks). (B) 
1A53- catalytic residues (cyan sticks) are overlaid with KE59 catalytic residues (grey sticks). 	  	  	  	  	  
	  
 
Fig. S10.  Michaelis-Menten plots of designed enzymes based on the scaffolds 1A53 
and 1THF.  Standard errors are calculated from three measurements. 	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